MedinCell receives $ 6.4 million grant from Unitaid to fight Malaria

March 25, 2020

The French company is committed to the fight against the major health scourges

• Malaria remains one of the main health threats worldwide with more than 200 million people infected yearly
• French company MedinCell has signed a grant agreement of up to $6.4 million over three years with global
health agency Unitaid that has committed to accelerate the impact of long-acting technologies in low- and
middle-income countries (LMICs)
• The grant aims to fund the formulation and preclinical activities of a 3-month acting injectable ivermectin – a
drug used to treat many types of parasitic infections – to neutralize the transmission vector of Malaria
• In accordance with the commitment of both partners to ensure equitable access to health products in low and middle income countries, and to have a significant impact on the most vulnerable populations, MedinCell will grant a non-exclusive license to the Medicines Patent Pool to ensure distribution of the final product via public sector in LMICs
• MedinCell will keep all other marketing rights of the product worldwide and for all additional indications where ivermectin could have an impact
• More than $ 25 million in grants over the next four years have already been awarded to MedinCell by major international non-profit foundations and organizations

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.